Expression and clinical significance of lncRNA TCL6 in serum of patients with preeclampsia

Wang,Hong; Shen,Guimei; Liu,Mengsi; Mao,Linjuan; Mao,Hui

doi:10.3892/etm.2021.10963

Expression and clinical significance of lncRNA TCL6 in serum of patients with preeclampsia

Authors:
- Hong Wang
- Guimei Shen
- Mengsi Liu
- Linjuan Mao
- Hui Mao
View Affiliations

Affiliations: Department of Obstetrics and Reproductive Center, The Affiliated Hospital of Yunnan University, Kunming, Yunnan 650000, P.R. China
Published online on: November 12, 2021 https://doi.org/10.3892/etm.2021.10963
Article Number: 41
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preeclampsia is a common syndrome in pregnancy and a leading cause of mortality of pregnant females and their infants. To investigate the diagnostic and prognostic utility of lncRNA T‑cell leukemia/lymphoma 6 (TCL6) in patients with preeclampsia, 120 singleton pregnant females with preeclampsia and another 100 healthy pregnant control subjects were analyzed in the present study. The expression of lncRNA TCL6 in the serum of the included patients was detected. Receiver operating characteristic curve analysis was applied to evaluate the efficiency of lncRNA TCL6 in terms of preeclampsia diagnosis and grading. Kaplan‑Meier analysis was adopted to assess the effect of lncRNA TCL6 expression on the rate of adverse pregnancy. Multivariate logistic regression was used to determine high‑risk factors of adverse pregnancy. The results indicated that lncRNA TCL6 was significantly increased in the serum of patients with preeclampsia. Furthermore, TCL6 was elevated in subgroups of patients with early‑onset or severe preeclampsia and with Haemolysis, Elevated Liver enzymes and Low Platelet count syndrome in comparison with other patients with preeclampsia. High expression of TCL6 in pregnant females corresponded to a higher rate of adverse pregnancy outcomes. Severe preeclampsia, early‑onset preeclampsia and high TCL6 expression were identified as independent risk factors for adverse pregnancy outcomes. For each unit increase in TCL6 expression, a 9.5‑fold increase of the risk of adverse maternal and fetal outcomes was determined. Collectively, high expression of lncRNA TCL6 may assist the diagnosis and grading of preeclampsia and may be adopted as an independent risk factor for adverse pregnancy outcomes.

View Figures

View References

1	Bokslag A, van Weissenbruch M, Mol BW and de Groot CJ: Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 102:47–50. 2016.PubMed/NCBI View Article : Google Scholar
2	Pauli JM and Repke JT: Preeclampsia: Short-term and Long-term Implications. Obstet Gynecol Clin North Am. 42:299–313. 2015.PubMed/NCBI View Article : Google Scholar
3	Ahmed A, Rezai H and Broadway-Stringer S: Evidence-Based Revised View of the Pathophysiology of Preeclampsia. Adv Exp Med Biol. 956:355–374. 2017.PubMed/NCBI View Article : Google Scholar
4	Balogun OA and Sibai BM: Counseling, Management, and Outcome in Women With Severe Preeclampsia at 23 to 28 Weeks' Gestation. Clin Obstet Gynecol. 60:183–189. 2017.PubMed/NCBI View Article : Google Scholar
5	Aloizos S, Seretis C, Liakos N, Aravosita P, Mystakelli C, Kanna E and Gourgiotis S: HELLP syndrome: Understanding and management of a pregnancy-specific disease. J Obstet Gynaecol. 33:331–337. 2013.PubMed/NCBI View Article : Google Scholar
6	Sones JL and Davisson RL: Preeclampsia, of mice and women. Physiol Genomics. 48:565–572. 2016.PubMed/NCBI View Article : Google Scholar
7	Nagy B: Cell-free nucleic acids in prenatal diagnosis and pregnancy-associated diseases. EJIFCC. 30:215–223. 2019.PubMed/NCBI
8	McAninch D, Roberts CT and Bianco-Miotto T: Mechanistic Insight into Long Noncoding RNAs and the Placenta. Int J Mol Sci. 18(18)2017.PubMed/NCBI View Article : Google Scholar
9	Saitou M, Sugimoto J, Hatakeyama T, Russo G and Isobe M: Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia. Oncogene. 19:2796–2802. 2000.PubMed/NCBI View Article : Google Scholar
10	Chen Z, Zhuang Q, Cheng K, Ming Y, Zhao Y, Ye Q and Zhang S: Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells. J Cancer. 11:1383–1392. 2020.PubMed/NCBI View Article : Google Scholar
11	Cuadros M, Andrades Á, Coira IF, Baliñas C, Rodríguez MI, Álvarez-Pérez JC, Peinado P, Arenas AM, García DJ, Jiménez P, et al: Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. Blood Cancer J. 9(93)2019.PubMed/NCBI View Article : Google Scholar
12	Luo LH, Jin M, Wang LQ, Xu GJ, Lin ZY, Yu DD, Yang SL, Ran RZ, Wu G and Zhang T: Long noncoding RNA TCL6 binds to miR-106a-5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathway. J Cell Physiol. 235:6154–6166. 2020.PubMed/NCBI View Article : Google Scholar
13	Zhang Y, Li Z, Chen M, Chen H, Zhong Q, Liang L and Li B: lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Breast Cancer. 27:573–585. 2020.PubMed/NCBI View Article : Google Scholar
14	Liu LP and Gong YB: LncRNA-TCL6 promotes early abortion and inhibits placenta implantation via the EGFR pathway. Eur Rev Med Pharmacol Sci. 22:7105–7112. 2018.PubMed/NCBI View Article : Google Scholar
15	Wu JL, Wang YG, Gao GM, Feng L, Guo N and Zhang CX: Overexpression of lncRNA TCL6 promotes preeclampsia progression by regulating PTEN. Eur Rev Med Pharmacol Sci. 23:4066–4072. 2019.PubMed/NCBI View Article : Google Scholar
16	No authors listed. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 122:1122–1131. 2013.PubMed/NCBI View Article : Google Scholar
17	Hypertensive Disorders in Pregnancy Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association and Hypertensive Disorders in Pregnancy Subgroup Chinese Society of Obstetrics and Gynecology Chinese Medical Association. Diagnosis and treatment guideline of hypertensive disorders in pregnancy. Zhonghua Fu Chan Ke Za Zhi. 50:721–728. 2015.PubMed/NCBI(In Chinese).
18	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008.PubMed/NCBI View Article : Google Scholar
19	Hui D and Hladunewich MA: Chronic Kidney Disease and Pregnancy. Obstet Gynecol. 133:1182–1194. 2019.PubMed/NCBI View Article : Google Scholar
20	Marsh CA and Hecker E: Maternal obesity and adverse reproductive outcomes: Reducing the risk. Obstet Gynecol Surv. 69:622–628. 2014.PubMed/NCBI View Article : Google Scholar
21	Reddy UM, Wapner RJ, Rebar RW and Tasca RJ: Infertility, assisted reproductive technology, and adverse pregnancy outcomes: Executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol. 109:967–977. 2007.PubMed/NCBI View Article : Google Scholar
22	Ashworth DC, Maule SP, Stewart F, Nathan HL, Shennan AH and Chappell LC: Setting and techniques for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev. 8(CD012739)2020.PubMed/NCBI View Article : Google Scholar
23	Han Q, Zheng W, Guo XD, Zhang D, Liu HF, Yu L and Yan JY: A new predicting model of preeclampsia based on peripheral blood test value. Eur Rev Med Pharmacol Sci. 24:7222–7229. 2020.PubMed/NCBI View Article : Google Scholar
24	Morris RK, Riley RD, Doug M, Deeks JJ and Kilby MD: Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: Systematic review and meta-analysis. BMJ. 345 (jul09 1)(e4342)2012.PubMed/NCBI View Article : Google Scholar
25	Song X, Luo X, Gao Q, Wang Y, Gao Q and Long W: Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia. Curr Drug Targets. 18:1165–1170. 2017.PubMed/NCBI View Article : Google Scholar
26	Cornette J, Herzog E, Buijs EA, Duvekot JJ, Rizopoulos D, Hop WC, Tibboel D and Steegers EA: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: A case-control study. BJOG. 121:363–370. 2014.PubMed/NCBI View Article : Google Scholar
27	Guida JPS, Surita FG, Parpinelli MA and Costa ML: Preterm Preeclampsia and Timing of Delivery: A Systematic Literature Review. Rev Bras Ginecol Obstet. 39:622–631. 2017.PubMed/NCBI View Article : Google Scholar
28	Lisonkova S and Joseph KS: Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 209:544.e1–544.e12. 2013.PubMed/NCBI View Article : Google Scholar
29	Li LJ, Wu XY, Tan SW, Xie ZJ, Pan XM, Pan SW, Bai WR, Li HJ, Liu HL, Jiang J, et al: Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients. Gastroenterol Rep (Oxf). 7:434–443. 2019.PubMed/NCBI View Article : Google Scholar
30	Tao S, Wang W, Liu P, Wang H and Chen W: Long non-coding RNA T-cell leukemia/lymphoma 6 serves as a sponge for miR-21 modulating the cell proliferation of retinoblastoma through PTEN. Korean J Physiol Pharmacol. 23:449–458. 2019.PubMed/NCBI View Article : Google Scholar
31	Redman C: The six stages of pre-eclampsia. Pregnancy Hypertens. 4(246)2014.PubMed/NCBI View Article : Google Scholar